CYP2C9 protein interactions with cytochrome b5: Effects on the coupling of catalysis

Drug Metabolism and Disposition

Volumn 35, Issue 7, 2007, Pages 1174-1181

  Locuson, Charles W ^a,d   Wienkers, Larry C ^b   Jones, Jeffrey P ^c   Tracy, Timothy S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b AMGEN INC   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' HYDROXYDICLOFENAC; 7 ETHOXYCOUMARIN; 7 HYDROXYWARFARIN; APOLIPOPROTEIN B5; CYTOCHROME B5; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 REDUCTASE; DICLOFENAC; DRUG METABOLITE; FLURBIPROFEN; GENE PRODUCT; HYDROGEN PEROXIDE; IRON; OXIDOREDUCTASE; OXYGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; WARFARIN; WATER;

AEROBIC METABOLISM; ARTICLE; CATALYSIS; CONFORMATION; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; RELIABILITY;

ALLOSTERIC REGULATION; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CATALYSIS; CYTOCHROMES B5; DICLOFENAC; FLURBIPROFEN; HEME; HUMANS; HYDROGEN PEROXIDE; KINETICS; MODELS, BIOLOGICAL; NADP; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDATION-REDUCTION; PROTEIN CONFORMATION; RATS; RECOMBINANT PROTEINS; WARFARIN; WATER;

EID: 34250776517     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.014910     Document Type: Article

References (32)

1. Anthon GE and Barrett DM (2003) Modified method for the determination of pyruvic acid with dinitrophenylhydrazine in the assessment of onion pungency. J Sci Food Agric 83:1210-1213.
2. Backes WL and Kelley RW (2003) Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes. Pharmacol Ther 98:221-233.
3. Crespi CL and Miller VP (1999) The use of heterologously expressed drug metabolizing enzymes - state of the art and prospects for the future. Pharmacol Ther 84:121-131.
4. Gorsky LD and Coon MJ (1986) Effects of conditions of reconstitution with cytochrome b5 on the formation of products in cytochrome P450-catalyzed reactions. Drug Metab Dispos 14:89-96.
5. Gruenke LD, Konopka K, Cadieu M, and Waskell L (1995) The stoichiometry of the cytochrome P-450-catalyzed metabolism of methoxyflurane and benzphetamine in the presence and absence of cytochrome b5. J Biol Chem 270:24707-24718.
6. Guengerich FP (1997) Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 43:7-35.
7. Guryev OL, Gilep AA, Usanov SA, and Estabrook RW (2001) Interaction of apo-cytochrome b5 with cytochromes P4503A4 and P45017A: relevance of heme transfer reactions. Biochemistry 40:5018-5031.
8. Haining RL, Jones JP, Henne KR, Fisher MB, Koop DR, Trager WF, and Rettie AE (1999) Enzymatic determinants of the substrate specificity of CYP2C9: Role of B′-C loop residues in providing the pi-stacking anchor site for warfarin binding. Biochemistry 38:3285-3292.
9. Hanna IH, Teiber JF, Kokones KL, and Hollenberg PF (1998) Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. Arch Biochem Biophys 350:324-332.
10. Jiang ZY, Woollard AC, and Wolff SP (1990) Hydrogen peroxide production during experimental protein glycation. FEBS Lett 268:69-71.
11. Jushchyshyn MI, Hutzler JM, Schrag ML, and Wienkers LC (2005) Catalytic turnover of pyrene by CYP3A4: evidence that cytochrome b5 directly induces positive cooperativity. Arch Biochem Biophys 438:21-28.
12. Kumar S, Davydov DR, and Halpert JR (2005) Role of cytochrome b5 in modulating peroxide-supported CYP3A4 activity: evidence for a conformational transition and cytochrome P450 heterogeneity. Drug Metab Dispos 33:1131-1136.
13. Kuzmic P (1996) Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase. Anal Biochem 237:260-273.
14. Lang D and Bocker R (1995) Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. J Chromatogr B Biomed Appl 672:305-309.
15. Locuson CW, Gannett PM, and Tracy TS (2006) Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9. Arch Biochem Biophys 449:115-129.
16. Morgan ET and Coon MJ (1984) Effects of cytochrome b5 on cytochrome P-450-catalyzed reactions. Studies with manganese-substituted cytochrome b5. Drug Metab Dispos 12:358-364.
17. Nakajima M, Tane K, Nakamura S, Shimada N, Yamazaki H, and Yokoi T (2002) Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b(5) in the expression system and the differences in the marker activities. J Pharm Sci 91:952-963.
18. Ollivon M, Lesieur S, Grabielle-Madelmont C, and Paternostre M (2000) Vesicle reconstitution from lipid-detergent mixed micelles. Biochim Biophys Acta 1508:34-50.
19. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
20. Perret A and Pompon D (1998) Electron shuttle between membrane-bound cytochrome P450 3A4 and b(5) rules uncoupling mechanisms. Biochemistry 37:11412-11424.
21. Porter TD (2002) The roles of cytochrome b5 in cytochrome P450 reactions. J Biochem Mol Toxicol 16:311-316.
22. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping - Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
23. Schenkman JB and Jansson I (2003) The many roles of cytochrome b5. Pharmacol Ther 97:139-152.
24. Tamburini PP, White RE, and Schenkman JB (1985) Chem characterization of protein-protein interactions between cytochrome P-450 and cytochrome b5. J Biol Chem 260:4007-40155.
25. Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, and Dickmann LJ (2002) Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos 30:385-390.
26. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, and Greenblatt DJ (2000) Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493-1504.
27. Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BJ, Rettie AE, and Cashman JR (1993) In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev 25:453-484.
28. Yamazaki H, Gillam EM, Dong MS, Johnson WW, Guengerich FP, and Shimada T (1997) Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b(5) interactions. Arch Biochem Biophys 342:329-337.
29. Yamazaki H, Johnson WW, Ueng YF, Shimada T, and Guengerich FP (1996a) Lack of electron transfer from cytochrome b(5) in stimulation of catalytic activities of cytochrome P450 3A4 - characterization of a reconstituted cytochrome P450 3A4 NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b(5). J Biol Chem 271:27438-27444.
30. Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Asahi S, Shimada N, Guengerich FP, Shimada T, Nakajima M, et al. (2002) Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr Purif 24:329-337.
31. Yamazaki H, Nakano M, Gillam EM, Bell LC, Guengerich FP, and Shimada T (1996b) Requirements for cytochrome b(5) in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes. Biochem Pharmacol 52:301-309.
32. Yamazaki H, Shimada T, Martin MV, and Guengerich FP (2001) Stimulation of cytochrome P450 reactions by apo-cytochrome b5: evidence against transfer of heme from cytochrome P450 3A4 to apo-cytochrome b5 or heme oxygenase. J Biol Chem 276:30885-30891.